Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2023	Oct. 02, 2022	Oct. 01, 2023	Oct. 02, 2022
Segment Reporting Information [Line Items]
Revenues		$ 13,232.0	$ 22,638.0	$ 44,247.0	$ 76,040.0
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(3,352.0)	9,001.0	5,187.0	29,498.0
Write-offs	[2]			5,847.0	476.0
Net gains/(losses) recognized during the period on equity securities	[3],[4]	(393.0)	(112.0)	(709.0)	(1,353.0)
Restructuring charges					701.0
Selling, informational and administrative expenses [Member]
Segment Reporting Information [Line Items]
Restructuring charges					344.0
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		30.0	112.0	213.0	237.0
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[5]	302.0	319.0	928.0	974.0
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1],[5]	(8,782.0)	(4,007.0)	(14,387.0)	(9,820.0)
Write-offs		5,600.0		5,800.0	500.0
Adjustment to cost of sales					900.0
Other Business Activities [Member] | Paxlovid
Segment Reporting Information [Line Items]
Charges to cost of sales related to raw materials			400.0		400.0
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(1,179.0)	(822.0)	(3,466.0)	(2,478.0)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	(227.0)	(62.0)	(778.0)	(331.0)
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1],[6]	(708.0)	(773.0)	(1,666.0)	(3,095.0)
Net gains/(losses) recognized during the period on equity securities				(711.0)	(1,300.0)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues		12,930.0	22,319.0	43,320.0	75,066.0
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		12,930.0	22,319.0	43,320.0	75,066.0
Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)	[1]	$ 7,545.0	$ 14,665.0	$ 25,484.0	$ 45,222.0

[1] Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss). Biopharma’s earnings include dividend income from our investment in ViiV of $30 million in the third quarter of 2023 and $112 million in the third quarter of 2022, and $213 million in the first nine months of 2023 and $237 million in the first nine months of 2022.

[2] See Notes 8 and 13.

[3] Reported in Other (income)/deductions––net. See Note 4.

[4] The net losses in the third quarter of 2023 include, among other things, unrealized losses of $312 million related to our investments in Cerevel Therapeutics Holdings, Inc. (Cerevel) and Allogene Therapeutics, Inc (Allogene). The net losses in the first nine months of 2023 include, among other things, unrealized losses of $606 million related to our investments in BioNTech, Cerevel and Allogene. The net losses in the first nine months of 2022 included, among other things, unrealized losses of $974 million related to our investments in BioNTech, Cerevel and Arvinas.

[5] Other business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&D expenses in the periods presented. Earnings in the third quarter and first nine months of 2023 include approximately $5.6 billion and $5.8 billion, respectively, of inventory write-offs and related charges to Cost of sales mainly due to lower-than-expected demand for our COVID-19 products. Earnings in the first nine months of 2022 included COVID-19-related charges of approximately $0.9 billion to Cost of sales, composed of (i) inventory write-offs of approximately $0.5 billion related to COVID-19 products that exceeded or were expected to exceed their approved shelf-lives prior to being used and (ii) charges of approximately $0.4 billion, primarily related to excess raw materials for Paxlovid recorded in the third quarter of 2022.

[6] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first nine months of 2023 include, among other items, net losses on equity securities of $711 million recorded in Other (income)/deductions––net. Earnings in the first nine months of 2022 included, among other items: (i) net losses on equity securities of $1.3 billion recorded in Other (income)/deductions––net and (ii) restructuring charges/(credits) and implementation costs and additional depreciation—asset restructuring of $701 million ($344 million recorded in Selling, informational and administrative expenses and the remaining amount primarily recorded in Restructuring charges and certain acquisition-related costs). See Note 4.